

18TH CIMT ANNUAL MEETING

MAINZ, MAY 5 – 7, 2020

Europe's Cancer Immunotherapy Meeting



Abstract Submission Guidelines

The Scientific Planning Committee will evaluate the scientific quality of the submitted abstracts on the basis of the following criteria: novelty of the research, significance of the findings, and clarity. Submitted abstracts should contain unpublished results. Authors should be particularly cognizant of the importance of setting forth the objectives and hypotheses of the study in a clear, succinct manner, and of summarizing their results. If an abstract is poorly written such that the Scientific Planning Committee cannot determine its novelty and importance, it will not be accepted for presentation at the conference. Authors must accept sole responsibility for the statements in their abstracts.

Authors submitting abstracts for presentation at this conference should consider the following:

1. All abstract PRESENTERS must first register to attend this conference.
2. The combined length of the abstract title and body should not exceed 3,000 characters (including spaces). The author and institution list is not included in the character limit. The online submission system will not accept abstracts that exceed this limit.
3. The following format for the title should be followed:
Title: sentence-style capitalization (e.g. The role of the tumor microenvironment in ...)
4. Titles should be indicative of the content of the abstract. All words necessary to identify the subject matter should be included in the title to facilitate electronic retrieval (if applicable). Avoid non-standard abbreviations in abstract titles.
5. Abstracts must describe in a succinct manner the purposes and results of the research so that the quality, novelty, and comprehensiveness of the work can be evaluated by the Abstract Committee. Each abstract should contain: (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the data; and (d) a statement of the conclusions. These should be provided as a single paragraph without any subheading.
6. Consistent American or British spelling should be used throughout.
7. Abbreviations may be used in the body of an abstract if they are defined at their first mention in the text. Complex therapeutic regimens must be identified.
8. No citation, figure, table, or any type of illustration should be added to the abstract.
9. When biological or chemical data pertaining to chemical entities are an integral part of the research, the chemical structure, method of preparation, and patent or reference numbers must be presented. If for any reason this information cannot be provided when the paper is presented at the conference, the abstract on this work should not be submitted for consideration.
10. Because of administrative and time constraints, supplemental data cannot be considered by the Scientific Planning Committee.
11. The authors are responsible for ensuring accuracy of the submitted abstract. Every effort will be made to publish the abstract exactly as submitted. Authors should prepare and proofread their abstracts carefully prior to submission. Errors made on your submitted abstract are likely to appear in print.
12. Authors are strongly encouraged to print a hard copy of their abstracts before submission.
13. Abstract submitters will receive an initial notification of receipt in the form of a confirmation screen. Notifications of abstract receipt and status/scheduling information will be sent to the email address provided for the abstract PRESENTER.